Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Competitiveness Cluster: Atlanpole Biotherapies Thematics: Biotechnologies / Health Main interests Immunology and immunotherapy Radiopharmaceuticals (“Isotop4Life”) Regenerative Medicine Keys Figures Financed projects : 59 Total cost of the projects: 184.3 M€ 1 - FUI projects: 24.8 M€ 2 - NRA projects: 42.3 M€ Achieved projects : 46 Patents (2011) : 48 Scientifics articles (2011) : 29 171 Members 4 intermediate-sized and large enterprises: Groupe Grimaud, Eurofins, Silliker SAS,… including 2 foreign companies: The MarkeTech Group (USA), Thermo Fisher Scientific (USA) 69 SMEs 98 centers of excellence: Universities of Angers and Nantes, Cancer Center ICO, ITUN (Transplantation Institute)… Figures : End 2011 (from evaluation 2012, 2008-2011 period ) Cluster Strengths Number of employees at cluster members: 1 900 Atlanpole Biotherapies is characterized by a fast increase of researchers number over the past decade – almost 1000 specialists dedicated to life-science - and the average development of 3 new biotech start ups every year. In order to ensure skilled people for the development of advanced therapies, a new training center, BIOPRACTIS, enables continuing education in clean rooms and training on the biopharmaceuticals producing process with pilot-scale industrial equipments. Atlanpole Biotherapies members focus their efforts on 3 major therapeutic areas: • 1 2 Immunobiotherapies with two specific focuses in tumor vaccination and autoimmune diseases/transplantation. We benefit from a strong history in the field of immunology with first applications designed for the transplantation and oncology therapeutic armamentarium development. This excellence lead to many company creations directly involved in, or related to, the business of antibodies or tumor vaccines. More recently the performance of the immunology community was rewarded by the French government granting the “IGO Labex” (“Immuno Graft Oncology laboratory of excellence) and of the “IHU CESTI project” (European Clinical Center for Transplantation Sciences). These two projects aim not only at improving recent developments in diagnostics and therapies in transplantation or oncology but also at developing next generation tools. Thus alternatives to organ grafts are developed and tested with cell and gene therapies techniques as well as combined biologics FUI : Single Interministerial Fund provides support for R&D projects between firms and laboratories from French cluster NRA : French National Research Agency provides support for academics projects approaches. Among audacious strategies developed in these projects, we can also mention the use of innovative radioisotopes that can be produced in the Arronax High-Energy cyclotron. • Radiopharmaceuticals with the creation of a dedicated hub “ISOTOP-4-LIFE”mixing academic & private competencies. Intensive research in nuclear imaging, targeted radionuclide therapy with radio-immunotherapy (RIT) and radiobiology is being performed around the high-energy and high-intensity cyclotron Arronax in Nantes. The main developments underway in nuclear imaging consist in innovative technologies for oncology, neurology and cardiac applications as well as improved measurement of radiopharmaceuticals biodistribution. RIT has shown promising results in clinical trials against cancers resistant to other treatments. RIT for cancers with poor prognosis is a focus of our cluster with special emphasis on a proprietary radio-labeled monoclonal antibody with completed Phase II clinical development to fight residual prostate cancer. Finally Atlanpole Biotherapies provides a comprehensive value chain for assessing your lead compounds namely trough a fully operating and open access “Whole Body Imaging HUB”. • Regenerative medicine including biomaterials as well as advanced therapies using cells and genes. Our strategy is supported by strong medical expertises in oncology, dermatology, cardiology, orthopedia and rare diseases and by specialized core facilities for immunomonitoring, biomanufacturing, developing and supplying a wide range of synthetic or viral carriers and by a strong know-how in experimental preclinical surgery and in safety tests development. Our community is also committed in various ambitious projects: • C4C, a national project aiming at structuring the large scale manufacturing of cell based therapeutic products. Our members are also leading a gene therapy manufacturing initiative (PGT industrial demonstrator facility). • The European R&D projects GAMBA (Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis) and REBORNE (Regenerating Bone Defects using New biomedical Engineering approaches) illustrate the strengths in the field of orthopedia. These successes also rely on a strong European networking culture of our players. An example of R&D Projects - GelTOP: The GelTOP collaborative project aims to develop hydrogels for in situ release of active ingredients in difficult situations such as bone tumors or unconsolidated fractures and thus allow bone reconstruction. Between 2009 to 2013, Biomatlante, the company project leader, developed an anticancer active ingredients encapsulation and controlled release system, to be more accurate and less invasive in complicated situations. The benefit for the patient is to prevent overdoses and successive medication. The company appealed to Inserm UMR 957 - to develop anticancer peptides, and to Atlantic Bone Screen company to undertake in vitro and in vivo trials.. Existing collaborations BCRT, BIOTOP, BIOREGIO Stern, Biome Tie.V, Heidelberg Technology Park, Germany Baltic Innovation Agency, Estonia Cardiff University, MEDILINK, Cornwall Development Company, UK SAN RAFFAELE Institut, Italy West BIC Galway, Ireland Insituto Andaluz de tecnologia, BIOMADRID, Spain ADRAL, UERN, Portugal BIOWIN, Belgium UPPSALA BIO, Sweden GOTEBORG BIO, Norway MEDCOAST Scandinavia, many countries LIOF, Netherland BIOPEOPLE, Denmark Contact e-mail for International Affairs: [email protected] web site : http://www.atlanpolebiotherapies.eu/ www.competitivite.gouv.fr www.competitivite.gouv.fr/en www.competitivite.gouv.fr/es Update : 01/09/2013